FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...
Healthline

Dosage Details for Doxycycline Oral Tablets and Capsules

Doxycycline is a generic prescription drug used to treat certain types of infections and other conditions. The drug comes as an oral tablet and oral capsule. Doxycycline belongs to a group of drugs ...
Medical News Today

Bactrim dosage

Bactrim is prescribed to treat certain infections, such as urinary tract infections or traveler’s diarrhea. Dosages of Bactrim may vary based on the condition being treated. Bactrim is typically taken ...
Seeking Alpha

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment VOQUEZNA represents the first major innovation in ...
Seeking Alpha

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK ...

Planning for a December 2023 U.S. launch for H. pylori, together with the U.S. launch of vonoprazan for Erosive GERD, if approved Adverse event (AE) rates for the vonoprazan-based regimens were ...
Healthline

Dosage Details of Hydrocodone Oral Forms

The prescribed dosage for hydrocodone may vary depending on your treatment plan. Factors such as your medical history and body weight may also affect your dosage. Hydrocodone is used in adults to ...
MedPage Today on MSN

New Pill Approved for Schizophrenia, Bipolar Disorder

Milsaperidone is an active metabolite of iloperidone ...

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European ...

Boehringer Ingelheim Limited: FDA approves HERNEXEOS, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...